(2R/S)-6-PNG 6-Prenylnaringenin; (±-6-Prenylnaringenin)|cas:68682-01-9|西域试剂

(2R/S)-6-PNG 6-Prenylnaringenin; (±-6-Prenylnaringenin),99.88%

产品编号：Bellancom-115681| CAS NO：68682-01-9| 分子式：C₂₀H₂₀O₅| 分子量：340.37

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-115681	￥2900.00	杭州北京（现货）
Bellancom-115681	￥4600.00	杭州北京（现货）
Bellancom-115681	￥9200.00	杭州北京（现货）
Bellancom-115681	￥14800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

(2R/S)-6-PNG 6-Prenylnaringenin; (±-6-Prenylnaringenin)

产品介绍

(2R/S)-6-PNG (6-Prenylnaringenin) 是一种有效且可逆的 Ca_v3.2 T 型 Ca²⁺ 通道 (T 通道)阻滞剂。(2R/S)-6-PNG 可以透过血脑屏障 (BBB)。(2R/S)-6-PNG 抑制小鼠的神经性和内脏疼痛。

生物活性

(2R/S)-6-PNG (6-Prenylnaringenin) is a potent and reversible Ca_v3.2 T-type Ca²⁺ channels (T-channels) blocker. (2R/S)-6-PNG can penetrate the blood-brain barrier (BBB). (2R/S)-6-PNG suppresses neuropathic and visceral pain in mice.

体外研究

(2R/S)-6-PNG (6-Prenylnaringenin) potently blocks Ca_v3.2, but exhibits minor effect on high-voltage-activated Ca²⁺ channels and voltage-gated Na⁺ channels in differentiated NG108-15 cells.
On the basis of IC50 values, the proportion (Ca_v3.2/HVA) of the inhibition potency of (2R/S)-6-PNG on Ca_v3.2 and HVA-currents is 5.20, and that (Ca_v3.2/Na_v) on Ca_v3.2 and Na_v-currents is 3.54.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

(2R/S)-6-PNG (6-Prenylnaringenin; 10-30 mg/kg; i.p.; single dose; 15 min before Na2S) significantly reduced the Na₂S-induced nociceptive behavior and/or referred hyperalgesia in onscious mice with intracolonic (i.col.) administration of Na₂S, an H₂S donor.
(2R/S)-6-PNG (30 mg/kg; i.p.) prevents the increased number of phosphorylated ERK-positive cells following i.col. Na2S in laminae I-II, V-VI and X to which the primary afferent neurons project, and the Na2S-induced increase in the phosphorylated ERK-positive cell number.
(2R/S)-6-PNG (0.01-1 and 0.1-10 nmol/paw; intraplantar administration) restores the mechanical allodynia induced by partial sciatic nerve ligation (PSNL) and by i.p. administration of Oxaliplatin (OHP) a, respectively, in a dose-dependent manner.
(2R/S)-6-PNG (20-30 mg/kg; i.p.) significantly reverses the PSNL-induced allodynia. (2R/S)-6-PNG (10-20 mg/kg; i.p.) significantly reverses the OHP-induced allodynia (5 mg/kg; i.p.; single dose).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (367.25 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.9380 mL	14.6899 mL	29.3798 mL
5 mM	0.5876 mL	2.9380 mL	5.8760 mL
10 mM	0.2938 mL	1.4690 mL	2.9380 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (6.11 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.11 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (6.11 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.11 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (6.11 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.11 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。